Is Alpa Laboratories a Good Buy After Its Q1 FY27 Results?
- September 7, 2026
- Posted by: Lakshit Sharma
- Category: Market
Alpa Laboratories share price around Rs 64. 35.7% below 52-week high of Rs 99. Q1 FY27 revenue Rs 30 crore, down 4.3% YoY. PAT Rs 0.98 crore, down 91.7%. PE 33x.
Quick Answer
Alpa Laboratories’ Q1 FY27 results were mixed, with revenue at Rs 30 crore but PAT falling 92% to Rs 0.98 crore. The Alpa Laboratories share price near Rs 64 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Alpa Laboratories is a good buy right now.
The Alpa Laboratories share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Alpa Laboratories is a manufacturer of pharmaceutical formulations, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.
Revenue for the quarter came in at Rs 30 crore, down 4.3% year on year, while profit after tax came in at Rs 0.98 crore, down 91.7% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Alpa Laboratories share price from here.
This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Alpa Laboratories share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.
Click Here – Get Free Investment Predictions
Alpa Laboratories Q1 FY27 Financial Highlights
| Metric | Q1 FY27 | Q1 FY26 | YoY Change |
|---|---|---|---|
| Revenue | Rs 30 crore | Rs 31 crore | -4.3% |
| EBITDA | Rs 1.81 crore | Rs 12 crore | -85.4% |
| Operating Margin | 7.6% | 64.7% | NA |
| Profit Before Tax | Rs 0.98 crore | Rs 12 crore | -91.7% |
| Net Profit / (Loss) | Rs 0.98 crore | Rs 12 crore | -91.7% |
Alpa Laboratories Q1 FY27 Performance Analysis
Check Alpa Laboratories Fundamentals on Univest Screener
Revenue declined 4.3% for the quarter, which was not offset by cost control, and the pharmaceutical formulations manufacturing business will need a stronger showing next quarter to reverse the trend.
Profitability is where the quarter disappointed. PAT fell 92% year on year to Rs 0.98 crore with revenue also down 4.3%, which points to margin or cost pressure that management will need to address. This gap between top-line and bottom-line performance is the key thing weighing on the Alpa Laboratories share price this quarter.
On a sequential basis, revenue moved down 4.9% sequentially from Rs 31 crore in the March 2026 quarter and net profit moved down 29.0% sequentially from Rs 1.38 crore in the prior quarter, giving a fuller picture of the trend behind the Alpa Laboratories share price than the year on year comparison alone.
Key Business Factors in Q1 FY27
Revenue Trend
Alpa Laboratories’ revenue declined 4.3% year on year this quarter, taking the quarterly base to Rs 30 crore in a pharmaceutical formulations manufacturing business that remains sensitive to demand and pricing cycles that ultimately feed through to the Alpa Laboratories share price.
Margin Movement
EBITDA fell to Rs 1.81 crore from Rs 12 crore, with operating margin slipping to 7.6% from 64.7%, pointing to cost or pricing pressure that management will need to manage through the rest of FY27.
Balance Sheet Position
Alpa Laboratories carries a low debt-to-equity ratio of 0.01, giving it a conservative balance sheet heading into the rest of FY27.
Valuation Context
The stock trades at a PE of 32.9x, below the industry average of 37.7x, which is worth factoring into any read of whether the Alpa Laboratories share price is expensive or reasonably priced.
Dividend Details
No interim dividend was declared alongside Alpa Laboratories’ Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Alpa Laboratories share price for income should watch the company’s announcements around its next annual results for any dividend decision.
Alpa Laboratories Share Price Outlook for FY27
The key question for the rest of FY27 is whether Alpa Laboratories can arrest the margin pressure seen this quarter. Revenue growth alone will not be enough to support the Alpa Laboratories share price if profitability keeps slipping, so investors should watch the next couple of quarters for signs of a turnaround in the bottom line.
A stabilising or improving margin trend in the next result would be the clearest signal that this quarter’s profit decline was a temporary setback rather than the start of a longer slide for the Alpa Laboratories share price.
Alpa Laboratories Stock Performance
Download the Univest iOS App or Univest Android App to track Alpa Laboratories’ live share price and get daily stock updates.
The Alpa Laboratories share price was trading around Rs 64 as results season played out in late August 2026, roughly 35.7% below its 52-week high of Rs 99 and well above its 52-week low of Rs 46. Promoter holding stood at 57.2% as of the June 2026 quarter.
The Alpa Laboratories share price has likely already absorbed some of this quarter’s disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of 8.06% and a book value of around Rs 89 per share, both useful reference points when judging whether the current price is reasonable.
Key Risks
Profitability Risk
The quarter’s profit trend is the clearest risk here. Until Alpa Laboratories shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.
Sector and Demand Risk
As a pharmaceutical formulations manufacturing business, Alpa Laboratories’ results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Alpa Laboratories share price well before the next result.
Execution Risk
Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
Conclusion
Alpa Laboratories’ Q1 FY27 results were weak on both counts, with PAT down 92% to Rs 0.98 crore, with revenue also falling 4.3%. The Alpa Laboratories share price reflects a stock in wait-and-watch mode, and it is not an obvious buy purely on this quarter’s numbers until both the topline and margin trend turn around.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Alpa Laboratories Q1 FY27 Results
What were Alpa Laboratories’ Q1 FY27 results?
Ans. Alpa Laboratories reported Q1 FY27 revenue of Rs 30 crore, down 4.3% year on year, and PAT of Rs 0.98 crore, down 91.7% year on year.
Is Alpa Laboratories a good buy after its Q1 FY27 results?
Ans. Alpa Laboratories’ profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.
What is the Alpa Laboratories share price today?
Ans. The Alpa Laboratories share price was trading around Rs 64 in late August 2026, about 35.7% below its 52-week high of Rs 99 and well above its 52-week low of Rs 46.
What is Alpa Laboratories’ revenue and profit for Q1 FY27?
Ans. Alpa Laboratories reported revenue of Rs 30 crore and a net profit of Rs 0.98 crore for the quarter ended June 30, 2026.
Did Alpa Laboratories declare a dividend with its Q1 FY27 results?
Ans. No interim dividend was declared alongside Alpa Laboratories’ Q1 FY27 results. Investors should track the company’s next annual results for any dividend announcement.
What is Alpa Laboratories’ PE ratio and is it expensive?
Ans. The Alpa Laboratories share price trades at a trailing PE of 32.9x, against an industry average of 37.7x. Investors should compare this with the company’s growth rate before judging value.
What are the key risks for Alpa Laboratories investors right now?
Ans. The quarter’s profit trend is the clearest risk here. Until Alpa Laboratories shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter’s trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.
What is Alpa Laboratories’ promoter shareholding?
Ans. Promoter holding in Alpa Laboratories stood at 57.2% as of the June 2026 quarter.